{"gene":"OLR1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2002,"finding":"LOX-1 is a Type II transmembrane protein with a C-type lectin-like extracellular domain; mutagenesis studies revealed that the lectin domain is the functional domain recognizing LOX-1 ligands, with C-terminal end residues and conserved positively charged residues spanning the lectin domain essential for OxLDL binding. The extracellular domains are post-translationally modified by N-linked glycosylation. LOX-1 can be cleaved by a protease at the extracellular juxtamembrane region to release a soluble form (sLOX-1).","method":"Active-site mutagenesis, glycosylation studies, cleavage/shedding assays","journal":"Pharmacology & therapeutics","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis identifying functional residues, glycosylation characterization, protease cleavage demonstrated; comprehensive review of original experimental findings replicated across studies","pmids":["12163130"],"is_preprint":false},{"year":2001,"finding":"LOX-1 supports adhesion of both Gram-positive (S. aureus) and Gram-negative (E. coli) bacteria to CHO-K1 cells stably expressing LOX-1 and to bovine aortic endothelial cells; binding was suppressed by poly(I) and anti-LOX-1 mAb, does not require divalent cations or serum factors, and functions under static and nonstatic conditions.","method":"Stable expression in CHO-K1 cells, FITC-labeled bacterial binding assay, antibody/inhibitor blockade","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding assay with gain-of-function cell model, antibody and chemical inhibitor confirmation, replicated in primary endothelial cells","pmids":["11290792"],"is_preprint":false},{"year":2006,"finding":"LOX-1 recognizes phosphatidylserine (PS) in a Ca2+-dependent manner; a recombinant, folded, and glycosylated LOX-1 binds PS but not other phospholipids; Ca2+ is specifically required (Mg2+ cannot substitute); LOX-1-mediated recognition of PS-containing apoptotic bodies was Ca2+-dependent and was abolished by bivalent-cation chelation, LOX-1-blocking antibodies, or PS-containing liposomes.","method":"Recombinant protein binding assay, lipid binding specificity panel, Ca2+/Mg2+ substitution experiments, apoptotic body recognition assay with antibody blockade","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted binding with purified recombinant protein, multiple orthogonal methods (lipid specificity, ion substitution, cell-based validation with blocking antibodies)","pmids":["16146427"],"is_preprint":false},{"year":2007,"finding":"The naturally occurring splice variant LOXIN (lacking part of the C-terminus lectin-like domain) inhibits LOX-1 function through hetero-oligomerization: LOXIN co-immunoprecipitates with LOX-1, forming non-functional hetero-oligomers that decrease LOX-1 plasma membrane localization and markedly impair ox-LDL binding and uptake.","method":"Co-immunoprecipitation, co-transfection of LOX-1 and LOXIN in mammalian fibroblasts and human endothelial cells, fluorescent ox-LDL uptake assay, plasma membrane localization assessment","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, functional ox-LDL uptake assay, and membrane localization analysis in two cell types; single lab but multiple orthogonal methods","pmids":["18191942"],"is_preprint":false},{"year":2014,"finding":"Endothelial-specific LOX-1 overexpression (using Tie2 promoter transgenic mice) increased aortic oxLDL uptake in endothelial cells but not macrophages, led to p38 phosphorylation, increased NF-κB activity and VCAM-1 upregulation, increased ROS production, impaired eNOS activity, and promoted macrophage accumulation and atherosclerotic plaque formation. Bone marrow transplantation showed endothelial LOX-1 alone was sufficient for atherosclerosis development.","method":"Endothelial-specific transgenic mouse model (Tie2 promoter), ApoE-/- double-mutant, bone marrow transplantation, western blotting, intravital imaging","journal":"European heart journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic mouse with cell-specific promoter, confirmed by bone marrow transplantation epistasis, multiple molecular endpoints","pmids":["24419805"],"is_preprint":false},{"year":2010,"finding":"SIRT1 reduces macrophage foam cell formation by diminishing LOX-1 expression via suppression of the NF-κB signaling pathway; partial SIRT1 deletion in atherosclerotic mice increased oxLDL accumulation in peritoneal macrophages and promoted foam cell formation; bone marrow-restricted SIRT1 deletion confirmed macrophage-specific SIRT1 function decreases atherogenesis through LOX-1.","method":"Heterozygous SIRT1 mouse model, bone marrow transplantation, peritoneal macrophage isolation, oxLDL uptake assays, NF-κB pathway analysis","journal":"European heart journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic deletion model confirmed by bone marrow transplantation, molecular pathway (NF-κB/LOX-1) identified","pmids":["20418343"],"is_preprint":false},{"year":2015,"finding":"All tested statins directly interact with the LOX-1 C-type lectin-like domain (CTLD), filling a hydrophobic tunnel in the recognition domain, displacing fluorescent ox-LDL binding. This interaction stabilizes the LOX-1 dimer, as confirmed by electrophoresis and western blot. Molecular docking and molecular dynamics simulations identified a 'CTLD clamp motion' enabling receptor-substrate coupling.","method":"Cell-based fluorescent ox-LDL displacement assay, molecular docking simulation, molecular dynamics simulation, electrophoretic separation and western blot of dimer assembly","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based binding assay plus computational docking, western blot of dimer; single lab, multiple methods but no crystal structure or direct mutagenesis validation","pmids":["25950192"],"is_preprint":false},{"year":2019,"finding":"SPPL2a/b (signal peptide peptidase-like 2a/b) perform intramembrane proteolysis of the membrane-bound N-terminal fragment (NTF) of LOX-1 generated after ectodomain shedding by ADAM10 and lysosomal degradation. LOX-1 NTFs self-associate via their transmembrane domain and activate MAP kinases in a ligand-independent manner, upregulating pro-atherogenic targets (ICAM-1, CTGF). SPPL2a/b-deficient mice accumulate LOX-1 NTFs and develop larger atherosclerotic plaques.","method":"Genetic mouse models (SPPL2a/b knockout), biochemical characterization of LOX-1 NTF, MAP kinase activation assays, identification of ADAM10 as sheddase, immunofluorescence, atherosclerosis plaque quantification","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout models combined with biochemical identification of cleavage products and downstream signaling, multiple orthogonal methods","pmids":["30819724"],"is_preprint":false},{"year":2014,"finding":"LOX-1-mediated ROS generation drives autophagy and mitochondrial DNA (mtDNA) damage, which in turn activates the NLRP3 inflammasome in THP-1 macrophages and primary macrophages; LOX-1 inhibition (by blocking antibody or siRNA) inhibited ROS generation, autophagy, mtDNA damage, and NLRP3 inflammasome expression. DNase II knockdown also inhibited autophagy and NLRP3, confirming the pathway: LOX-1 → ROS → mtDNA damage → autophagy → NLRP3 activation.","method":"siRNA knockdown, blocking antibody, ROS inhibitors, autophagy inducer/inhibitor, DNase II siRNA, THP-1 and primary macrophages","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple siRNA/inhibitor interventions at different steps; single lab, but orthogonal genetic and pharmacological tools confirming pathway order","pmids":["24776598"],"is_preprint":false},{"year":2015,"finding":"LOX-1 and PCSK9 positively regulate each other's expression; siRNA knockdown of PCSK9 reduced LOX-1 expression and function, while recombinant PCSK9 enhanced LOX-1 expression; conversely, LOX-1 siRNA reduced PCSK9 expression and LOX-1 overexpression increased PCSK9. In LOX-1 KO mice, PCSK9 was decreased; in PCSK9 KO mice, LOX-1 was decreased. Mitochondrial ROS (mtROS) initiates the LOX-1/PCSK9 interaction.","method":"siRNA knockdown, cDNA overexpression, recombinant protein treatment, LOX-1 KO and PCSK9 KO mouse models, western blotting, mtROS inhibitors","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — bidirectional siRNA/overexpression in cells, confirmed in two separate gene KO mouse models; multiple orthogonal approaches","pmids":["26092101"],"is_preprint":false},{"year":2014,"finding":"LOX-1 pathway activation is involved in determining the extent of myocardial ischemia-reperfusion injury; LOX-1 expression is induced in cardiac myocytes following ischemia-reperfusion (but not ischemia alone). Administration of anti-LOX-1 monoclonal antibody reduced myocardial infarction size by ~50% in rats.","method":"Rat coronary artery ligation/reperfusion model, immunohistochemistry, anti-LOX-1 monoclonal antibody treatment, infarct size measurement","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function via antibody blockade with quantitative phenotypic readout; single lab, single intervention method","pmids":["12507499"],"is_preprint":false},{"year":2001,"finding":"Statins (simvastatin and atorvastatin) attenuate ox-LDL-induced upregulation of LOX-1 and downregulation of eNOS in human coronary artery endothelial cells; ox-LDL-mediated MAP kinase activation was also inhibited by statins, suggesting inhibition of LOX-1 and subsequently MAP kinase activity as a mechanism of statin cardioprotection.","method":"Cell-based assay with human coronary artery endothelial cells, western blotting for LOX-1 and eNOS, MAP kinase activation assay, dose-response with two different statins","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single lab, pharmacological modulation with dose-response, two orthogonal protein readouts; no genetic confirmation","pmids":["11735125"],"is_preprint":false},{"year":2014,"finding":"LPS induces LOX-1 expression via the TLR4/MyD88/Nox4-ROS/p38MAPK/NF-κB signaling pathway in endothelial cells; siRNA for TLR4, MyD88, and Nox4 each blocked LPS-induced LOX-1 upregulation, as did inhibitors of p38MAPK, NF-κB, and NADPH oxidase. LOX-1-mediated ox-LDL uptake and monocyte-endothelial adhesion were inhibited by anti-LOX-1 antibody.","method":"siRNA knockdown of TLR4, MyD88, Nox4; pharmacological inhibitors; western blotting; DiI-ox-LDL uptake assay; monocyte adhesion assay; in vivo mouse LPS injection","journal":"Vascular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple siRNA targets and pathway inhibitors defining signal hierarchy; single lab, confirmed in vivo","pmids":["25135647"],"is_preprint":false},{"year":2015,"finding":"LOX-1 inhibition impairs macrophage migration in response to ox-LDL; LOX-1 mediates ox-LDL-induced upregulation of calpain-2 and downregulation of calpain-1, and increases intracellular Ca2+; LOX-1 knockout macrophages show higher calpain-1 expression, lower calpain-2, improved migration, and lower Ca2+ compared to wild-type after ox-LDL treatment.","method":"LOX-1 knockout mouse peritoneal macrophages, wild-type comparison, calpain expression western blotting, cell migration assay, intracellular Ca2+ measurement","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with defined cellular phenotype (migration) and molecular mechanism (calpain-1/2 regulation); single lab","pmids":["26393906"],"is_preprint":false},{"year":2015,"finding":"Membrane cholesterol depletion (by MβCD) triggers release of full-length LOX-1 in exosomes and promotes ectodomain shedding to generate soluble LOX-1 (sLOX-1); endothelial cells secrete a soluble metalloproteinase responsible for LOX-1 ectodomain shedding; long-term statin treatment enhances sLOX-1 proteolytic shedding.","method":"Cholesterol modulation by MβCD and statins, exosome isolation, western blotting for full-length and truncated forms, metalloproteinase inhibition assay, stable and transient LOX-1 expression in endothelial cells","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical fractionation, multiple cholesterol-modulating agents and metalloproteinase inhibition; single lab, multiple orthogonal methods","pmids":["26495844"],"is_preprint":false},{"year":2011,"finding":"LOX-1 transcription is upregulated by ox-LDL through an Oct-1 binding motif at nt -1556 of the human LOX-1 promoter, and by angiotensin II through an NF-κB motif at nt -2158; Oct-1-mediated upregulation represents an early transcriptional event in LOX-1 stimulation by ox-LDL, creating a positive feedback loop.","method":"Promoter analysis, transcription factor binding site mapping, reporter assays","journal":"Cardiovascular drugs and therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mapping with defined transcription factor binding sites; single lab review of experimental data, specific nucleotide positions identified","pmids":["21796333"],"is_preprint":false},{"year":2018,"finding":"miR-98 directly targets LOX-1 mRNA (validated by luciferase reporter assay); miR-98 mimics decreased LOX-1 expression and inhibited foam cell formation and lipid accumulation in macrophages; miR-98 inhibitors had opposite effects; effects confirmed in ApoE-/- mice in vivo.","method":"Luciferase reporter assay (3'UTR), miR-98 mimics and inhibitors in peritoneal macrophages, ApoE-/- mouse model with agomiR-98 and antagomiR-98","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct target validation by luciferase reporter, bidirectional miRNA manipulation in vitro and confirmed in vivo in mouse model","pmids":["29549823"],"is_preprint":false},{"year":2015,"finding":"The rs1050286 SNP in the OLR1 3'UTR alters LOX-1 expression by modifying miR-24 binding affinity; luciferase assays showed miR-24 targets OLR1 3'UTR-G but not 3'UTR-A; overexpression of miR-24 in HeLa cells (heterozygous A/G) but not HepG2 cells (homozygous A/A) significantly downregulated OLR1 mRNA and protein.","method":"Luciferase reporter assay with OLR1 3'UTR alleles, miR-24 overexpression in genotyped cell lines, RT-PCR and western blotting","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional validation of SNP effect on miRNA-mediated repression by luciferase and allele-specific cell line comparison; single lab","pmids":["26542080"],"is_preprint":false},{"year":2020,"finding":"HRD1 (E3 ubiquitin ligase) interacts with LOX-1 and promotes ubiquitination and proteasomal degradation of LOX-1, thereby preventing ox-LDL-induced endothelial cell apoptosis; LOX-1 deletion attenuated endothelial apoptosis induced by HRD1 downregulation; transcription factor KLF2 positively regulates HRD1 expression and pravastatin enhanced HRD1 expression through a KLF2-dependent mechanism.","method":"Co-immunoprecipitation of HRD1 with LOX-1, ubiquitination assay, HRD1 overexpression and LOX-1 siRNA knockdown, endothelial apoptosis assay, KLF2/promoter binding assay","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying E3 ligase-substrate interaction, ubiquitination confirmed, functional apoptosis readout; single lab","pmids":["32308114"],"is_preprint":false},{"year":2016,"finding":"LOX-1 mediates inflammatory activation of microglial cells through the p38-MAPK/NF-κB pathway under hypoxic-ischemic conditions; NF-κB and HIF-1α bind to the OLR1 gene promoter region (confirmed by chromatin immunoprecipitation and luciferase reporter assay); LOX-1 expression in microglial cells is autonomously maintained by positive feedback of the intracellular LOX-1 signaling pathway.","method":"Primary rat microglial cells, oxygen-glucose deprivation model, siRNA, p38-MAPK inhibitor, NF-κB inhibitor, luciferase reporter assay, chromatin immunoprecipitation assay (ChIP), ROS assay, cytokine measurement","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP validation of transcription factor binding to OLR1 promoter, multiple inhibitor/siRNA interventions; single lab, single cell type","pmids":["37268943"],"is_preprint":false},{"year":2022,"finding":"Nrf2 directly binds to the LOX-1 promoter sequence and positively regulates LOX-1 transcriptional and translational activity; Nrf2 deficiency in ApoE-/- mice diminished LOX-1 expression and attenuated VSMC proliferation and migration, reducing atherosclerotic plaque burden; confirmed by dual luciferase reporter and immunoprecipitation assays.","method":"Dual luciferase reporter assay, immunoprecipitation, Nrf2-siRNA in VSMCs, Apoe-/-Nrf2-/- double knockout mouse model, proliferation and migration assays","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter interaction confirmed by luciferase reporter and IP, genetic knockout with cellular phenotype; single lab","pmids":["35299056"],"is_preprint":false},{"year":2024,"finding":"LOX-1 acts as a membrane receptor for H. pylori catalase, mediating bacterial adhesion to gastric epithelial cells; LOX-1 mRNA is a key target regulated by m6A modification (added by METTL3), which destabilizes LOX-1 mRNA and reduces LOX-1 protein levels; pharmacological inhibition or genetic ablation of LOX-1 reduces H. pylori colonization; deletion of bacterial catalase decreases adhesion to human gastric sections.","method":"m6A-seq, siRNA against m6A methylases, Mettl3 hemizygous mouse model, LOX-1 pharmacological inhibition and genetic knockout, bacterial adhesion assay, identification of LOX-1 as receptor for H. pylori catalase","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic LOX-1 ablation and bacterial catalase deletion confirm receptor-ligand specificity, m6A regulation confirmed biochemically, multiple orthogonal methods in cells and in vivo","pmids":["38253620"],"is_preprint":false},{"year":2016,"finding":"LOX-1 knockdown in H9C2 cardiomyocytes significantly ameliorated hypoxia-induced cell hypertrophy and reduced oxidative stress; mechanistically, LOX-1/NOX2/NOX4/ROS pathway underlies hypoxia-induced right ventricular hypertrophy; LOX-1 knockdown attenuated NOX2/4 expression and ROS generation.","method":"siRNA knockdown of LOX-1 in H9C2 cells and rat model, immunofluorescence, western blotting, DCFH-DA ROS assay, rat hypoxia model","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with quantified hypertrophy and molecular readouts in vitro and in vivo; single lab","pmids":["28259654"],"is_preprint":false},{"year":2017,"finding":"OLR1 increases HMGA2 transcription by upregulating c-Myc expression to promote metastasis of pancreatic cancer cells; OLR1 promoted proliferation and metastasis in vitro and in vivo.","method":"OLR1 overexpression and knockdown in pancreatic cancer cell lines, in vivo xenograft mouse model, c-Myc and HMGA2 expression analysis","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss- and gain-of-function with defined molecular pathway (OLR1→c-Myc→HMGA2); single lab, in vitro and in vivo confirmation","pmids":["32019809"],"is_preprint":false},{"year":2017,"finding":"TBC1D3 oncogene upregulates OLR1 expression at the transcriptional level via activation of the TNFα/NF-κB signaling pathway; OLR1 depletion (by siRNA or pomalidomide) significantly decreased TBC1D3-induced migration of breast cancer cells; TBC1D3 increased TNFα release, elevated TNFR1/TRAF transcription, and decreased TNFR1 degradation to activate NF-κB.","method":"siRNA knockdown of OLR1, TBC1D3 overexpression, NF-κB inhibitor caffeic acid phenethyl ester, pomalidomide (TNFα inhibitor), cell migration assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and pharmacological inhibition with quantified migration phenotype; pathway placement via NF-κB inhibition; single lab","pmids":["28844714"],"is_preprint":false},{"year":2011,"finding":"OLR1 overexpression activates NF-κB (p65) and upregulates pro-oncogenic NF-κB target genes involved in apoptosis inhibition (BCL2, BCL2A1, TNFAIP3) and cell cycle regulation (CCND2) in both MCF10A and HCC1143 cell lines; OLR1 overexpression in HCC1143 cells enhanced cell migration; OLR1 neutralizing antibody inhibited adhesion and transendothelial migration of untreated HCC1143 cells; OLR1 KO mice showed broad inhibition of NF-κB target genes and de novo lipogenesis genes.","method":"OLR1 overexpression, OLR1 KO mouse microarray, neutralizing antibody, cell migration assay, cell adhesion and transendothelial migration assay, transcriptome analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function combined with KO mouse transcriptome; single lab, multiple orthogonal methods","pmids":["21637860"],"is_preprint":false},{"year":2013,"finding":"LOX-1 in cardiac fibroblasts supports cytoskeletal organization and proliferation; as fibroblasts senesce, LOX-1 expression decreases; transfection of senescent fibroblasts with h-LOX-1 restored cytoskeletal organization, partially restored CDC42 and p70 S6 kinase expression, enhanced proliferation, and restored Mdm2 and phospho-Akt expression.","method":"Serial passage and aging mouse cardiac fibroblast isolation, LOX-1 cDNA transfection, cytoskeleton imaging, western blotting for CDC42, p70 S6 kinase, Mdm2, Akt","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — gain-of-function rescue with molecular readouts; single lab, single cell type, no genetic KO comparison","pmids":["23648807"],"is_preprint":false},{"year":2016,"finding":"miR-590-5p targets LOX-1 mRNA; Ang II downregulates miR-590-5p and upregulates LOX-1 in HUVECs; miR-590-5p mimics reduced LOX-1 expression and attenuated Ang II-induced apoptosis and ROS generation; LOX-1 siRNA or neutralizing antibody (TS92) reduced apoptosis and inhibited caspase-3 activation and cytochrome C release.","method":"miR-590-5p mimics, LOX-1 siRNA, LOX-1 neutralizing antibody (TS92), flow cytometry for apoptosis, western blotting for caspase-3 and cytochrome C, DCFH-DA for ROS","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional miRNA manipulation, genetic and antibody LOX-1 blockade, multiple apoptosis readouts; single lab","pmids":["26906623"],"is_preprint":false},{"year":2023,"finding":"Klotho inhibits ox-LDL deposition in podocytes in diabetic kidney disease by reducing IGF-1R expression, which decreases RAC1 expression and enhances mitochondrial function, ultimately reducing OLR1 expression and renal ox-LDL deposition.","method":"Klotho genotype mouse model (STZ-induced DKD), in vitro podocyte experiments, siRNA/inhibitor targeting IGF-1R and RAC1, western blotting and immunofluorescence","journal":"Cardiovascular diabetology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic mouse model and in vitro pathway dissection (IGF-1R/RAC1/OLR1); single lab, multiple interventions","pmids":["37891556"],"is_preprint":false}],"current_model":"OLR1/LOX-1 is a Type II transmembrane C-type lectin scavenger receptor that recognizes and internalizes oxidized LDL, phosphatidylserine (Ca2+-dependent), apoptotic cells, activated platelets, bacteria (S. aureus, E. coli), and H. pylori catalase via its C-terminal lectin-like domain; upon ligand binding it activates NF-κB, p38-MAPK, and ROS-generating pathways to drive endothelial dysfunction, macrophage foam cell formation, VSMC proliferation, and inflammation in atherosclerosis; its activity is regulated proteolytically by ADAM10 (ectodomain shedding generating sLOX-1) and SPPL2a/b (intramembrane cleavage of the residual NTF, which otherwise activates MAP kinases independently of ligand), by ubiquitin-proteasomal degradation via HRD1, by its dominant-negative splice variant LOXIN (which forms non-functional hetero-oligomers reducing plasma membrane LOX-1), transcriptionally by NF-κB, HIF-1α, Oct-1, and Nrf2, and post-transcriptionally by miR-24, miR-98, and miR-590-5p; it engages in mutual positive regulation with PCSK9, is downregulated by SIRT1 (via NF-κB suppression), and is directly bound and stabilized in its hydrophobic tunnel by statins."},"narrative":{"mechanistic_narrative":"OLR1/LOX-1 is a Type II transmembrane C-type lectin-like scavenger receptor whose C-terminal lectin domain mediates recognition and internalization of multiple ligands, driving vascular inflammation and atherogenesis [PMID:12163130, PMID:24419805]. Its lectin-like extracellular domain is N-glycosylated, and active-site mutagenesis identified conserved positively charged residues required for oxidized LDL binding; the domain also binds phosphatidylserine in a strictly Ca2+-dependent manner (enabling apoptotic-body recognition), adheres Gram-positive and Gram-negative bacteria independently of divalent cations, and serves as a receptor for H. pylori catalase to mediate gastric colonization [PMID:12163130, PMID:11290792, PMID:16146427, PMID:38253620]. Ligand engagement activates p38-MAPK and NF-κB signaling and ROS generation, upregulating adhesion molecules (VCAM-1, ICAM-1) and impairing eNOS; endothelial-specific LOX-1 overexpression is sufficient to drive macrophage accumulation and atherosclerotic plaque formation in vivo [PMID:24419805, PMID:30819724]. Downstream of receptor activation, LOX-1-generated ROS cause mitochondrial DNA damage and autophagy that activate the NLRP3 inflammasome, regulate calpain-1/calpain-2 balance and intracellular Ca2+ to control macrophage migration, and engage the NOX2/NOX4 axis in cardiomyocyte hypertrophy [PMID:24776598, PMID:26393906, PMID:28259654]. LOX-1 is subject to multilayered control: ADAM10-mediated ectodomain shedding releases soluble LOX-1 and leaves a membrane N-terminal fragment that self-associates and activates MAP kinases ligand-independently until cleared by SPPL2a/b intramembrane proteolysis; HRD1-dependent ubiquitination targets it for proteasomal degradation; and the splice variant LOXIN hetero-oligomerizes with LOX-1 to reduce its surface expression [PMID:18191942, PMID:30819724, PMID:32308114]. Its expression is transcriptionally driven by Oct-1, NF-κB, HIF-1α, and Nrf2 through defined promoter elements, repressed by SIRT1 via NF-κB suppression, and post-transcriptionally tuned by miR-98, miR-24, miR-590-5p, and m6A methylation [PMID:20418343, PMID:21796333, PMID:29549823, PMID:35299056]. LOX-1 engages in mutual positive regulation with PCSK9 initiated by mitochondrial ROS, and statins directly bind its lectin-domain hydrophobic tunnel to displace ox-LDL and stabilize the receptor dimer [PMID:26092101, PMID:25950192]. Beyond the vasculature, OLR1 promotes proliferation and metastasis of pancreatic and breast cancer cells through c-Myc/HMGA2 induction and NF-κB target gene activation [PMID:32019809, PMID:28844714, PMID:21637860].","teleology":[{"year":2001,"claim":"Established that LOX-1 is a pattern-recognition receptor with ligand breadth beyond oxidized LDL, binding bacteria independently of cations or serum.","evidence":"FITC-labeled bacterial binding to LOX-1-expressing CHO-K1 and aortic endothelial cells with antibody/inhibitor blockade","pmids":["11290792"],"confidence":"High","gaps":["Binding motif on bacteria not defined","physiological consequence of bacterial binding not addressed"]},{"year":2001,"claim":"Linked statins to LOX-1 by showing they suppress ox-LDL-induced LOX-1 upregulation and downstream MAP kinase activation, framing a cardioprotective mechanism.","evidence":"Western blotting for LOX-1/eNOS and MAP kinase assays in human coronary artery endothelial cells with two statins","pmids":["11735125"],"confidence":"Medium","gaps":["No genetic confirmation","did not distinguish transcriptional vs post-translational effects"]},{"year":2002,"claim":"Defined the structural basis of ligand recognition, locating the functional binding determinants in the C-type lectin domain and documenting glycosylation and ectodomain shedding.","evidence":"Active-site mutagenesis, glycosylation studies, and cleavage/shedding assays","pmids":["12163130"],"confidence":"High","gaps":["Sheddase identity not established here","no atomic structure of ligand-bound domain"]},{"year":2006,"claim":"Showed LOX-1 directly and selectively recognizes phosphatidylserine in a Ca2+-dependent manner, providing a molecular basis for apoptotic-cell clearance.","evidence":"Recombinant folded glycosylated protein lipid-specificity panel, Ca2+/Mg2+ substitution, apoptotic-body recognition with blocking antibodies","pmids":["16146427"],"confidence":"High","gaps":["Ca2+ coordination site not mapped","in vivo relevance of PS recognition not tested"]},{"year":2007,"claim":"Identified a dominant-negative regulatory mechanism whereby the splice variant LOXIN suppresses LOX-1 by hetero-oligomerization and reduced surface localization.","evidence":"Reciprocal Co-IP and ox-LDL uptake/membrane localization assays in fibroblasts and endothelial cells","pmids":["18191942"],"confidence":"High","gaps":["Stoichiometry of hetero-oligomers unknown","endogenous LOXIN regulation not defined"]},{"year":2010,"claim":"Placed SIRT1 as a negative regulator of LOX-1, reducing macrophage foam cell formation through NF-κB suppression.","evidence":"SIRT1 heterozygous and bone-marrow-restricted deletion in atherosclerotic mice with macrophage oxLDL uptake assays","pmids":["20418343"],"confidence":"High","gaps":["Direct SIRT1 target at the OLR1 locus not defined","deacetylation substrate in the pathway unidentified"]},{"year":2011,"claim":"Mapped stimulus-specific transcriptional control of OLR1, identifying an Oct-1 element responding to ox-LDL and an NF-κB element responding to angiotensin II, defining a feed-forward loop.","evidence":"Promoter mapping, transcription-factor binding-site analysis, reporter assays","pmids":["21796333"],"confidence":"Medium","gaps":["ChIP confirmation of Oct-1 occupancy not shown","in vivo relevance of specific sites not tested"]},{"year":2011,"claim":"Extended OLR1 function to oncogenesis, showing it activates NF-κB target genes promoting survival, cell cycle, and migration in breast epithelial/cancer cells.","evidence":"Overexpression, KO mouse transcriptome microarray, neutralizing antibody, adhesion/transendothelial migration assays","pmids":["21637860"],"confidence":"Medium","gaps":["Ligand driving tumor NF-κB activation unclear","mechanism of surface signaling in cancer not dissected"]},{"year":2013,"claim":"Revealed a non-scavenging role in which LOX-1 supports cytoskeletal organization and proliferation in cardiac fibroblasts, declining with senescence.","evidence":"LOX-1 cDNA rescue of senescent fibroblasts with CDC42/p70S6K/Mdm2/Akt readouts and cytoskeleton imaging","pmids":["23648807"],"confidence":"Medium","gaps":["No KO comparison","direct link from receptor to cytoskeletal effectors not established"]},{"year":2014,"claim":"Demonstrated that endothelial LOX-1 alone is sufficient to drive atherosclerosis via p38/NF-κB, ROS, VCAM-1, and eNOS impairment.","evidence":"Endothelial-specific Tie2 transgenic mice on ApoE-/- background with bone marrow transplantation epistasis and intravital imaging","pmids":["24419805"],"confidence":"High","gaps":["Relative contribution of macrophage LOX-1 not isolated here","structural basis of receptor signaling not addressed"]},{"year":2014,"claim":"Defined an ordered intracellular cascade by which LOX-1-driven ROS cause mtDNA damage and autophagy to activate the NLRP3 inflammasome.","evidence":"siRNA, blocking antibody, ROS/autophagy modulators, and DNase II knockdown in THP-1 and primary macrophages","pmids":["24776598"],"confidence":"Medium","gaps":["Single lab","in vivo confirmation of the inflammasome axis not shown"]},{"year":2014,"claim":"Showed LPS induces LOX-1 through a defined TLR4/MyD88/Nox4-ROS/p38/NF-κB hierarchy, connecting innate immune signaling to receptor upregulation.","evidence":"siRNA of TLR4/MyD88/Nox4, pathway inhibitors, ox-LDL uptake and monocyte adhesion assays, in vivo LPS injection","pmids":["25135647"],"confidence":"Medium","gaps":["Direct promoter target downstream of NF-κB not mapped here","single lab"]},{"year":2014,"claim":"Implicated the LOX-1 pathway in myocardial ischemia-reperfusion injury, with induction specific to reperfusion and antibody blockade halving infarct size.","evidence":"Rat coronary ligation/reperfusion model with anti-LOX-1 mAb and infarct quantification","pmids":["12507499"],"confidence":"Medium","gaps":["Ligand driving reperfusion induction unclear","single intervention method"]},{"year":2015,"claim":"Established reciprocal positive regulation between LOX-1 and PCSK9 initiated by mitochondrial ROS, linking two atherogenic factors.","evidence":"Bidirectional siRNA/overexpression/recombinant protein in cells confirmed in LOX-1 KO and PCSK9 KO mice with mtROS inhibitors","pmids":["26092101"],"confidence":"High","gaps":["Molecular mediator of the cross-regulation not identified","whether interaction is direct or indirect unresolved"]},{"year":2015,"claim":"Showed statins directly bind the LOX-1 lectin-domain hydrophobic tunnel, displacing ox-LDL and stabilizing the receptor dimer.","evidence":"Cell-based ox-LDL displacement, molecular docking/dynamics, and electrophoresis/western blot of dimer assembly","pmids":["25950192"],"confidence":"Medium","gaps":["No crystal structure","binding residues not validated by mutagenesis"]},{"year":2015,"claim":"Identified cholesterol-dependent release routes for LOX-1, including exosomal export of full-length receptor and metalloproteinase-mediated ectodomain shedding enhanced by statins.","evidence":"MβCD/statin cholesterol modulation, exosome isolation, metalloproteinase inhibition, western blotting in endothelial cells","pmids":["26495844"],"confidence":"Medium","gaps":["Specific metalloproteinase not identified here","functional role of exosomal LOX-1 unclear"]},{"year":2015,"claim":"Connected a 3'UTR SNP (rs1050286) to allele-specific miR-24 repression of OLR1, providing a genetic mechanism for expression variation.","evidence":"Luciferase assays with OLR1 3'UTR alleles and miR-24 overexpression in genotyped cell lines","pmids":["26542080"],"confidence":"Medium","gaps":["Population-level phenotype not linked","single lab"]},{"year":2015,"claim":"Showed LOX-1 controls macrophage migration via calpain-1/calpain-2 balance and intracellular Ca2+ in response to ox-LDL.","evidence":"LOX-1 KO peritoneal macrophages, calpain western blotting, migration and Ca2+ assays","pmids":["26393906"],"confidence":"Medium","gaps":["Mechanism linking receptor to calpain switch not defined","single lab"]},{"year":2016,"claim":"Identified miR-590-5p as a repressor of LOX-1 protecting endothelial cells from angiotensin II-induced apoptosis and ROS.","evidence":"miR-590-5p mimics, LOX-1 siRNA/neutralizing antibody, apoptosis flow cytometry, caspase-3/cytochrome C western blotting","pmids":["26906623"],"confidence":"Medium","gaps":["Direct 3'UTR binding validation limited","in vivo confirmation absent"]},{"year":2016,"claim":"Extended hypoxia-driven LOX-1 signaling to microglia, with ChIP-confirmed NF-κB and HIF-1α promoter binding and an autonomous positive-feedback loop.","evidence":"Oxygen-glucose deprivation in primary microglia, ChIP, luciferase reporters, siRNA and pathway inhibitors","pmids":["37268943"],"confidence":"Medium","gaps":["In vivo neuroinflammation relevance not tested","single cell type"]},{"year":2016,"claim":"Implicated LOX-1 in hypoxia-induced cardiomyocyte hypertrophy through a NOX2/NOX4/ROS pathway.","evidence":"LOX-1 siRNA in H9C2 cells and rat hypoxia model with hypertrophy and ROS readouts","pmids":["28259654"],"confidence":"Medium","gaps":["Receptor ligand in hypoxia unclear","single lab"]},{"year":2017,"claim":"Showed OLR1 promotes pancreatic cancer proliferation and metastasis through a c-Myc/HMGA2 transcriptional axis.","evidence":"Overexpression/knockdown in pancreatic cancer lines, xenograft model, c-Myc/HMGA2 expression analysis","pmids":["32019809"],"confidence":"Medium","gaps":["Link from surface receptor to c-Myc induction not mechanistically resolved","single lab"]},{"year":2017,"claim":"Placed OLR1 downstream of the TBC1D3 oncogene via TNFα/NF-κB signaling driving breast cancer migration.","evidence":"TBC1D3 overexpression, OLR1 siRNA/pomalidomide, NF-κB inhibitor, migration assays","pmids":["28844714"],"confidence":"Medium","gaps":["Direct OLR1 promoter occupancy not shown","single lab"]},{"year":2019,"claim":"Resolved the proteolytic fate of LOX-1, showing ADAM10 sheds the ectodomain and SPPL2a/b clear the residual NTF, which otherwise self-associates to activate MAP kinases ligand-independently and drive atherosclerosis.","evidence":"SPPL2a/b knockout mice, biochemical characterization of NTF, MAP kinase assays, plaque quantification","pmids":["30819724"],"confidence":"High","gaps":["Structural basis of NTF self-association undefined","regulation of ADAM10 shedding in vivo not detailed"]},{"year":2020,"claim":"Identified HRD1 as the E3 ligase ubiquitinating LOX-1 for proteasomal degradation, with KLF2-driven HRD1 protecting endothelium from ox-LDL-induced apoptosis.","evidence":"Co-IP, ubiquitination assay, HRD1 overexpression/LOX-1 siRNA, apoptosis assay, KLF2 promoter binding","pmids":["32308114"],"confidence":"Medium","gaps":["Ubiquitination site on LOX-1 not mapped","single lab"]},{"year":2022,"claim":"Established Nrf2 as a direct positive transcriptional regulator of LOX-1 promoting VSMC proliferation and plaque burden.","evidence":"Dual luciferase reporter, immunoprecipitation, Nrf2 siRNA in VSMCs, ApoE-/-Nrf2-/- double-knockout mice","pmids":["35299056"],"confidence":"Medium","gaps":["Exact Nrf2 response element not delineated","single lab"]},{"year":2023,"claim":"Connected Klotho-dependent IGF-1R/RAC1 signaling to OLR1 suppression, reducing ox-LDL deposition in diabetic kidney podocytes.","evidence":"Klotho genotype STZ-DKD mouse model and podocyte IGF-1R/RAC1 siRNA/inhibitor experiments","pmids":["37891556"],"confidence":"Medium","gaps":["Direct transcriptional control of OLR1 not shown","single lab"]},{"year":2024,"claim":"Identified LOX-1 as the host receptor for H. pylori catalase mediating gastric colonization, and showed METTL3-driven m6A destabilizes OLR1 mRNA.","evidence":"m6A-seq, METTL3 siRNA/Mettl3 hemizygous mice, LOX-1 inhibition/knockout, bacterial catalase deletion adhesion assays","pmids":["38253620"],"confidence":"High","gaps":["Catalase-binding interface on LOX-1 not mapped","downstream signaling from this interaction not defined"]},{"year":null,"claim":"How LOX-1's diverse ligand recognition is structurally encoded and translated into distinct downstream signaling outputs across cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of ligand-bound LOX-1","no defined transmembrane signaling adaptor for the receptor","mechanism distinguishing ligand-dependent from NTF-mediated signaling unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0,1,2,21]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[1,21]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[4,7]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,4]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[14]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,8,12,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,7,9]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,23,24]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[7,18]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[15,16,20]}],"complexes":[],"partners":["LOXIN","PCSK9","HRD1","ADAM10","SPPL2A","SPPL2B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P78380","full_name":"Oxidized low-density lipoprotein receptor 1","aliases":["C-type lectin domain family 8 member A","Lectin-like oxidized LDL receptor 1","LOX-1","Lectin-like oxLDL receptor 1","hLOX-1","Lectin-type oxidized LDL receptor 1"],"length_aa":273,"mass_kda":31.0,"function":"Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria (Microbial infection) May serve as a receptor for adhesin A variant 3 (nadA) of N.meningitidis","subcellular_location":"Cell membrane; Cell membrane; Membrane raft; Secreted","url":"https://www.uniprot.org/uniprotkb/P78380/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/OLR1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/OLR1","total_profiled":1310},"omim":[{"mim_id":"612088","title":"C-TYPE LECTIN DOMAIN FAMILY 12, MEMBER A; CLEC12A","url":"https://www.omim.org/entry/612088"},{"mim_id":"608446","title":"MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/608446"},{"mim_id":"606783","title":"C-TYPE LECTIN DOMAIN FAMILY 1, MEMBER B; CLEC1B","url":"https://www.omim.org/entry/606783"},{"mim_id":"606782","title":"C-TYPE LECTIN DOMAIN FAMILY 1, MEMBER A; CLEC1A","url":"https://www.omim.org/entry/606782"},{"mim_id":"606264","title":"C-TYPE LECTIN DOMAIN FAMILY 7, MEMBER A; CLEC7A","url":"https://www.omim.org/entry/606264"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":94.3},{"tissue":"placenta","ntpm":107.4}],"url":"https://www.proteinatlas.org/search/OLR1"},"hgnc":{"alias_symbol":["LOX-1","SCARE1","CLEC8A"],"prev_symbol":[]},"alphafold":{"accession":"P78380","domains":[{"cath_id":"3.10.100.10","chopping":"148-266","consensus_level":"high","plddt":95.8634,"start":148,"end":266},{"cath_id":"1.20.5","chopping":"39-139","consensus_level":"medium","plddt":94.3683,"start":39,"end":139}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P78380","model_url":"https://alphafold.ebi.ac.uk/files/AF-P78380-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P78380-F1-predicted_aligned_error_v6.png","plddt_mean":87.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=OLR1","jax_strain_url":"https://www.jax.org/strain/search?query=OLR1"},"sequence":{"accession":"P78380","fasta_url":"https://rest.uniprot.org/uniprotkb/P78380.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P78380/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P78380"}},"corpus_meta":[{"pmid":"23935243","id":"PMC_23935243","title":"LOX-1, OxLDL, and atherosclerosis.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/23935243","citation_count":603,"is_preprint":false},{"pmid":"12163130","id":"PMC_12163130","title":"LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis.","date":"2002","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/12163130","citation_count":319,"is_preprint":false},{"pmid":"29737246","id":"PMC_29737246","title":"Role of Ox-LDL and LOX-1 in Atherogenesis.","date":"2019","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29737246","citation_count":252,"is_preprint":false},{"pmid":"21947818","id":"PMC_21947818","title":"Oxidized LDL, LOX-1 and atherosclerosis.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21947818","citation_count":243,"is_preprint":false},{"pmid":"23124189","id":"PMC_23124189","title":"LOX-1 in atherosclerosis: biological functions and pharmacological modifiers.","date":"2012","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/23124189","citation_count":242,"is_preprint":false},{"pmid":"31336709","id":"PMC_31336709","title":"LOX-1: Regulation, Signaling and Its Role in Atherosclerosis.","date":"2019","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31336709","citation_count":205,"is_preprint":false},{"pmid":"26092101","id":"PMC_26092101","title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26092101","citation_count":205,"is_preprint":false},{"pmid":"20418343","id":"PMC_20418343","title":"SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis.","date":"2010","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/20418343","citation_count":190,"is_preprint":false},{"pmid":"31746997","id":"PMC_31746997","title":"PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1.","date":"2020","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/31746997","citation_count":184,"is_preprint":false},{"pmid":"11290792","id":"PMC_11290792","title":"LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11290792","citation_count":144,"is_preprint":false},{"pmid":"28571642","id":"PMC_28571642","title":"LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation.","date":"2017","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28571642","citation_count":143,"is_preprint":false},{"pmid":"21338316","id":"PMC_21338316","title":"Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis.","date":"2011","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21338316","citation_count":143,"is_preprint":false},{"pmid":"21805404","id":"PMC_21805404","title":"The discovery of LOX-1, its ligands and clinical significance.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21805404","citation_count":130,"is_preprint":false},{"pmid":"24776598","id":"PMC_24776598","title":"LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis.","date":"2014","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/24776598","citation_count":117,"is_preprint":false},{"pmid":"29462603","id":"PMC_29462603","title":"LOX-1 receptor: A potential link in atherosclerosis and cancer.","date":"2018","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29462603","citation_count":112,"is_preprint":false},{"pmid":"26607724","id":"PMC_26607724","title":"Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis.","date":"2015","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26607724","citation_count":102,"is_preprint":false},{"pmid":"19801851","id":"PMC_19801851","title":"Lox-1: the multifunctional receptor underlying cardiovascular dysfunction.","date":"2009","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/19801851","citation_count":101,"is_preprint":false},{"pmid":"21637860","id":"PMC_21637860","title":"Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21637860","citation_count":100,"is_preprint":false},{"pmid":"24419805","id":"PMC_24419805","title":"Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo.","date":"2014","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/24419805","citation_count":95,"is_preprint":false},{"pmid":"11735125","id":"PMC_11735125","title":"Inhibition of LOX-1 by statins may relate to upregulation of eNOS.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11735125","citation_count":95,"is_preprint":false},{"pmid":"12646194","id":"PMC_12646194","title":"Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12646194","citation_count":92,"is_preprint":false},{"pmid":"33402733","id":"PMC_33402733","title":"LOX-1 and cancer: an indissoluble liaison.","date":"2021","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33402733","citation_count":89,"is_preprint":false},{"pmid":"23799016","id":"PMC_23799016","title":"Celastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stress.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23799016","citation_count":89,"is_preprint":false},{"pmid":"15271788","id":"PMC_15271788","title":"Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells.","date":"2004","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15271788","citation_count":87,"is_preprint":false},{"pmid":"31514732","id":"PMC_31514732","title":"Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.","date":"2019","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31514732","citation_count":85,"is_preprint":false},{"pmid":"24886290","id":"PMC_24886290","title":"LOX-1 and ROS, inseparable factors in the process of endothelial damage.","date":"2014","source":"Free radical research","url":"https://pubmed.ncbi.nlm.nih.gov/24886290","citation_count":82,"is_preprint":false},{"pmid":"16146427","id":"PMC_16146427","title":"LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells.","date":"2006","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16146427","citation_count":79,"is_preprint":false},{"pmid":"30381837","id":"PMC_30381837","title":"Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives.","date":"2018","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30381837","citation_count":77,"is_preprint":false},{"pmid":"11004213","id":"PMC_11004213","title":"Expression of LOX-1, an oxidized low-density lipoprotein receptor, in experimental hypertensive glomerulosclerosis.","date":"2000","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/11004213","citation_count":71,"is_preprint":false},{"pmid":"31447588","id":"PMC_31447588","title":"LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31447588","citation_count":67,"is_preprint":false},{"pmid":"18191942","id":"PMC_18191942","title":"The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization.","date":"2007","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/18191942","citation_count":62,"is_preprint":false},{"pmid":"21993919","id":"PMC_21993919","title":"LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21993919","citation_count":61,"is_preprint":false},{"pmid":"25135647","id":"PMC_25135647","title":"Lipopolysaccharide induced LOX-1 expression via TLR4/MyD88/ROS activated p38MAPK-NF-κB pathway.","date":"2014","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25135647","citation_count":60,"is_preprint":false},{"pmid":"27160316","id":"PMC_27160316","title":"LOX-1-Mediated Effects on Vascular Cells in Atherosclerosis.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27160316","citation_count":59,"is_preprint":false},{"pmid":"28844714","id":"PMC_28844714","title":"Up-regulation of OLR1 expression by TBC1D3 through activation of TNFα/NF-κB pathway promotes the migration of human breast cancer cells.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28844714","citation_count":50,"is_preprint":false},{"pmid":"32019809","id":"PMC_32019809","title":"OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2.","date":"2020","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/32019809","citation_count":49,"is_preprint":false},{"pmid":"26907636","id":"PMC_26907636","title":"Roles of LOX-1 in microvascular dysfunction.","date":"2016","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26907636","citation_count":47,"is_preprint":false},{"pmid":"10865829","id":"PMC_10865829","title":"Oxidized-LDL and atherosclerosis. Role of LOX-1.","date":"2000","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10865829","citation_count":47,"is_preprint":false},{"pmid":"22777292","id":"PMC_22777292","title":"LOX-1: a multiligand receptor at the crossroads of response to danger signals.","date":"2012","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/22777292","citation_count":47,"is_preprint":false},{"pmid":"30639239","id":"PMC_30639239","title":"LOX-1 and atherosclerotic-related diseases.","date":"2019","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30639239","citation_count":46,"is_preprint":false},{"pmid":"24959993","id":"PMC_24959993","title":"LOX-1, oxidant stress, mtDNA damage, autophagy, and immune response in atherosclerosis.","date":"2014","source":"Canadian journal of physiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24959993","citation_count":46,"is_preprint":false},{"pmid":"25950192","id":"PMC_25950192","title":"Molecular mechanism of statin-mediated LOX-1 inhibition.","date":"2015","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25950192","citation_count":43,"is_preprint":false},{"pmid":"27694040","id":"PMC_27694040","title":"LOX-1 and TLR4 affect each other and regulate the generation of ROS in A. fumigatus keratitis.","date":"2016","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27694040","citation_count":43,"is_preprint":false},{"pmid":"33262811","id":"PMC_33262811","title":"Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice.","date":"2020","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33262811","citation_count":42,"is_preprint":false},{"pmid":"30963716","id":"PMC_30963716","title":"Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway.","date":"2019","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/30963716","citation_count":42,"is_preprint":false},{"pmid":"21861069","id":"PMC_21861069","title":"LOX-1 and angiotensin receptors, and their interplay.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21861069","citation_count":41,"is_preprint":false},{"pmid":"12507499","id":"PMC_12507499","title":"LOX-1 pathway affects the extent of myocardial ischemia-reperfusion injury.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12507499","citation_count":41,"is_preprint":false},{"pmid":"25463747","id":"PMC_25463747","title":"LOX-1 in atherosclerotic disease.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25463747","citation_count":40,"is_preprint":false},{"pmid":"28084571","id":"PMC_28084571","title":"Xanthine Oxidase Induces Foam Cell Formation through LOX-1 and NLRP3 Activation.","date":"2017","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28084571","citation_count":40,"is_preprint":false},{"pmid":"26578342","id":"PMC_26578342","title":"Structure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density Lipoprotein.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26578342","citation_count":40,"is_preprint":false},{"pmid":"29549823","id":"PMC_29549823","title":"MicroRNA-98 regulates foam cell formation and lipid accumulation through repression of LOX-1.","date":"2018","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/29549823","citation_count":40,"is_preprint":false},{"pmid":"28146073","id":"PMC_28146073","title":"LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28146073","citation_count":35,"is_preprint":false},{"pmid":"26666837","id":"PMC_26666837","title":"The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26666837","citation_count":34,"is_preprint":false},{"pmid":"31350594","id":"PMC_31350594","title":"Upregulated LOX-1 Receptor: Key Player of the Pathogenesis of Atherosclerosis.","date":"2019","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/31350594","citation_count":34,"is_preprint":false},{"pmid":"30819724","id":"PMC_30819724","title":"Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30819724","citation_count":34,"is_preprint":false},{"pmid":"24000272","id":"PMC_24000272","title":"Oxidized LDL and LOX-1 in experimental sepsis.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24000272","citation_count":32,"is_preprint":false},{"pmid":"35608341","id":"PMC_35608341","title":"The oxidized-LDL/LOX-1 axis in tumor endothelial cells enhances metastasis by recruiting neutrophils and cancer cells.","date":"2022","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35608341","citation_count":32,"is_preprint":false},{"pmid":"21796333","id":"PMC_21796333","title":"LOX-1 transcription.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21796333","citation_count":31,"is_preprint":false},{"pmid":"37268943","id":"PMC_37268943","title":"LOX-1 mediates inflammatory activation of microglial cells through the p38-MAPK/NF-κB pathways under hypoxic-ischemic conditions.","date":"2023","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/37268943","citation_count":31,"is_preprint":false},{"pmid":"26906623","id":"PMC_26906623","title":"MiR-590-5p-meidated LOX-1 upregulation promotes Angiotensin II-induced endothelial cell apoptosis.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26906623","citation_count":31,"is_preprint":false},{"pmid":"30172652","id":"PMC_30172652","title":"Wnt5a contributes to dectin-1 and LOX-1 induced host inflammatory response signature in Aspergillus fumigatus keratitis.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30172652","citation_count":31,"is_preprint":false},{"pmid":"21881850","id":"PMC_21881850","title":"LOX-1 and obesity.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21881850","citation_count":30,"is_preprint":false},{"pmid":"31608230","id":"PMC_31608230","title":"Targeting LOX-1 Inhibits Colorectal Cancer Metastasis in an Animal Model.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31608230","citation_count":30,"is_preprint":false},{"pmid":"15309203","id":"PMC_15309203","title":"The role of LOX-1, a novel lectin-like receptor for oxidized low density lipoprotein, in atherosclerosis.","date":"2004","source":"The Canadian journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15309203","citation_count":29,"is_preprint":false},{"pmid":"31593304","id":"PMC_31593304","title":"Wnt5a is involved in LOX-1 and TLR4 induced host inflammatory response in peri-implantitis.","date":"2019","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/31593304","citation_count":28,"is_preprint":false},{"pmid":"32308114","id":"PMC_32308114","title":"HRD1 prevents atherosclerosis-mediated endothelial cell apoptosis by promoting LOX-1 degradation.","date":"2020","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/32308114","citation_count":27,"is_preprint":false},{"pmid":"30718451","id":"PMC_30718451","title":"Pro-oncogenic action of LOX-1 and its splice variant LOX-1Δ4 in breast cancer phenotypes.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30718451","citation_count":27,"is_preprint":false},{"pmid":"16606746","id":"PMC_16606746","title":"Association of the OLR1 gene with milk composition in Holstein dairy cattle.","date":"2006","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/16606746","citation_count":27,"is_preprint":false},{"pmid":"37891556","id":"PMC_37891556","title":"Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease.","date":"2023","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/37891556","citation_count":26,"is_preprint":false},{"pmid":"21912849","id":"PMC_21912849","title":"Novel concepts in the genesis of hypertension: role of LOX-1.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21912849","citation_count":26,"is_preprint":false},{"pmid":"21709374","id":"PMC_21709374","title":"Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: genetics and expression analysis.","date":"2011","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/21709374","citation_count":25,"is_preprint":false},{"pmid":"35269979","id":"PMC_35269979","title":"Myeloperoxidase-Oxidized LDL Activates Human Aortic Endothelial Cells through the LOX-1 Scavenger Receptor.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35269979","citation_count":25,"is_preprint":false},{"pmid":"35299056","id":"PMC_35299056","title":"Nrf2 deficiency attenuates atherosclerosis by reducing LOX-1-mediated proliferation and migration of vascular smooth muscle cells.","date":"2022","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/35299056","citation_count":25,"is_preprint":false},{"pmid":"21968594","id":"PMC_21968594","title":"Angiogenesis is a link between atherosclerosis and tumorigenesis: role of LOX-1.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21968594","citation_count":24,"is_preprint":false},{"pmid":"29859535","id":"PMC_29859535","title":"Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29859535","citation_count":24,"is_preprint":false},{"pmid":"35391927","id":"PMC_35391927","title":"Reducing the Damage of Ox-LDL/LOX-1 Pathway to Vascular Endothelial Barrier Can Inhibit Atherosclerosis.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35391927","citation_count":24,"is_preprint":false},{"pmid":"26495844","id":"PMC_26495844","title":"Membrane Cholesterol Modulates LOX-1 Shedding in Endothelial Cells.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26495844","citation_count":24,"is_preprint":false},{"pmid":"23892036","id":"PMC_23892036","title":"Design of a novel LOX-1 receptor antagonist mimicking the natural substrate.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23892036","citation_count":23,"is_preprint":false},{"pmid":"17022953","id":"PMC_17022953","title":"G501C polymorphism of oxidized LDL receptor gene (OLR1) and ischemic stroke.","date":"2006","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17022953","citation_count":23,"is_preprint":false},{"pmid":"32182251","id":"PMC_32182251","title":"LOX-1: A potential driver of cardiovascular risk in SLE patients.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32182251","citation_count":22,"is_preprint":false},{"pmid":"34118114","id":"PMC_34118114","title":"Effects of Apigenin on the Expression of LOX-1, Bcl-2, and Bax in Hyperlipidemia Rats.","date":"2021","source":"Chemistry & biodiversity","url":"https://pubmed.ncbi.nlm.nih.gov/34118114","citation_count":22,"is_preprint":false},{"pmid":"24634093","id":"PMC_24634093","title":"15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells.","date":"2014","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24634093","citation_count":22,"is_preprint":false},{"pmid":"34439368","id":"PMC_34439368","title":"Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34439368","citation_count":21,"is_preprint":false},{"pmid":"31998315","id":"PMC_31998315","title":"Immunological Outcomes Mediated Upon Binding of Heat Shock Proteins to Scavenger Receptors SCARF1 and LOX-1, and Endocytosis by Mononuclear Phagocytes.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31998315","citation_count":21,"is_preprint":false},{"pmid":"32793587","id":"PMC_32793587","title":"LOX-1 Regulates P. gingivalis-Induced Monocyte Migration and Adhesion to Human Umbilical Vein Endothelial Cells.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32793587","citation_count":21,"is_preprint":false},{"pmid":"28259654","id":"PMC_28259654","title":"LOX-1 promotes right ventricular hypertrophy in hypoxia-exposed rats.","date":"2017","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28259654","citation_count":21,"is_preprint":false},{"pmid":"38791315","id":"PMC_38791315","title":"LOX-1 in Cardiovascular Disease: A Comprehensive Molecular and Clinical Review.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38791315","citation_count":20,"is_preprint":false},{"pmid":"21904818","id":"PMC_21904818","title":"LOX-1/LOXIN: the yin/yang of atheroscleorosis.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21904818","citation_count":20,"is_preprint":false},{"pmid":"26393906","id":"PMC_26393906","title":"LOX-1 in macrophage migration in response to ox-LDL and the involvement of calpains.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26393906","citation_count":20,"is_preprint":false},{"pmid":"26542080","id":"PMC_26542080","title":"The human rs1050286 polymorphism alters LOX-1 expression through modifying miR-24 binding.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26542080","citation_count":20,"is_preprint":false},{"pmid":"27077384","id":"PMC_27077384","title":"Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27077384","citation_count":20,"is_preprint":false},{"pmid":"28898769","id":"PMC_28898769","title":"LOX-1 is involved in IL-1β production and extracellular matrix breakdown in dental peri-implantitis.","date":"2017","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28898769","citation_count":20,"is_preprint":false},{"pmid":"23391848","id":"PMC_23391848","title":"OLR1, PON1 and MTHFR gene polymorphisms, conventional risk factors and the severity of coronary atherosclerosis in a Chinese Han population.","date":"2013","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23391848","citation_count":20,"is_preprint":false},{"pmid":"21847544","id":"PMC_21847544","title":"LOX-1: a critical player in the genesis and progression of myocardial ischemia.","date":"2011","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21847544","citation_count":19,"is_preprint":false},{"pmid":"33553253","id":"PMC_33553253","title":"Proteolytic Regulation of the Lectin-Like Oxidized Lipoprotein Receptor LOX-1.","date":"2021","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33553253","citation_count":19,"is_preprint":false},{"pmid":"37089448","id":"PMC_37089448","title":"Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome.","date":"2023","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/37089448","citation_count":19,"is_preprint":false},{"pmid":"24157503","id":"PMC_24157503","title":"LOX-1: a male hormone-regulated scavenger receptor for atherosclerosis.","date":"2013","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24157503","citation_count":19,"is_preprint":false},{"pmid":"38253620","id":"PMC_38253620","title":"LOX-1 acts as an N6-methyladenosine-regulated receptor for Helicobacter pylori by binding to the bacterial catalase.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38253620","citation_count":18,"is_preprint":false},{"pmid":"39123116","id":"PMC_39123116","title":"Dysregulated lipid metabolism and intervertebral disc degeneration: the important role of ox-LDL/LOX-1 in endplate chondrocyte senescence and calcification.","date":"2024","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/39123116","citation_count":18,"is_preprint":false},{"pmid":"23648807","id":"PMC_23648807","title":"LOX-1 in the maintenance of cytoskeleton and proliferation in senescent cardiac fibroblasts.","date":"2013","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23648807","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52558,"output_tokens":8403,"usd":0.141859,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18055,"output_tokens":7507,"usd":0.138975,"stage2_stop_reason":"end_turn"},"total_usd":0.280834,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"LOX-1 is a Type II transmembrane protein with a C-type lectin-like extracellular domain; mutagenesis studies revealed that the lectin domain is the functional domain recognizing LOX-1 ligands, with C-terminal end residues and conserved positively charged residues spanning the lectin domain essential for OxLDL binding. The extracellular domains are post-translationally modified by N-linked glycosylation. LOX-1 can be cleaved by a protease at the extracellular juxtamembrane region to release a soluble form (sLOX-1).\",\n      \"method\": \"Active-site mutagenesis, glycosylation studies, cleavage/shedding assays\",\n      \"journal\": \"Pharmacology & therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis identifying functional residues, glycosylation characterization, protease cleavage demonstrated; comprehensive review of original experimental findings replicated across studies\",\n      \"pmids\": [\"12163130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"LOX-1 supports adhesion of both Gram-positive (S. aureus) and Gram-negative (E. coli) bacteria to CHO-K1 cells stably expressing LOX-1 and to bovine aortic endothelial cells; binding was suppressed by poly(I) and anti-LOX-1 mAb, does not require divalent cations or serum factors, and functions under static and nonstatic conditions.\",\n      \"method\": \"Stable expression in CHO-K1 cells, FITC-labeled bacterial binding assay, antibody/inhibitor blockade\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding assay with gain-of-function cell model, antibody and chemical inhibitor confirmation, replicated in primary endothelial cells\",\n      \"pmids\": [\"11290792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LOX-1 recognizes phosphatidylserine (PS) in a Ca2+-dependent manner; a recombinant, folded, and glycosylated LOX-1 binds PS but not other phospholipids; Ca2+ is specifically required (Mg2+ cannot substitute); LOX-1-mediated recognition of PS-containing apoptotic bodies was Ca2+-dependent and was abolished by bivalent-cation chelation, LOX-1-blocking antibodies, or PS-containing liposomes.\",\n      \"method\": \"Recombinant protein binding assay, lipid binding specificity panel, Ca2+/Mg2+ substitution experiments, apoptotic body recognition assay with antibody blockade\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted binding with purified recombinant protein, multiple orthogonal methods (lipid specificity, ion substitution, cell-based validation with blocking antibodies)\",\n      \"pmids\": [\"16146427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The naturally occurring splice variant LOXIN (lacking part of the C-terminus lectin-like domain) inhibits LOX-1 function through hetero-oligomerization: LOXIN co-immunoprecipitates with LOX-1, forming non-functional hetero-oligomers that decrease LOX-1 plasma membrane localization and markedly impair ox-LDL binding and uptake.\",\n      \"method\": \"Co-immunoprecipitation, co-transfection of LOX-1 and LOXIN in mammalian fibroblasts and human endothelial cells, fluorescent ox-LDL uptake assay, plasma membrane localization assessment\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, functional ox-LDL uptake assay, and membrane localization analysis in two cell types; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"18191942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Endothelial-specific LOX-1 overexpression (using Tie2 promoter transgenic mice) increased aortic oxLDL uptake in endothelial cells but not macrophages, led to p38 phosphorylation, increased NF-κB activity and VCAM-1 upregulation, increased ROS production, impaired eNOS activity, and promoted macrophage accumulation and atherosclerotic plaque formation. Bone marrow transplantation showed endothelial LOX-1 alone was sufficient for atherosclerosis development.\",\n      \"method\": \"Endothelial-specific transgenic mouse model (Tie2 promoter), ApoE-/- double-mutant, bone marrow transplantation, western blotting, intravital imaging\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic mouse with cell-specific promoter, confirmed by bone marrow transplantation epistasis, multiple molecular endpoints\",\n      \"pmids\": [\"24419805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SIRT1 reduces macrophage foam cell formation by diminishing LOX-1 expression via suppression of the NF-κB signaling pathway; partial SIRT1 deletion in atherosclerotic mice increased oxLDL accumulation in peritoneal macrophages and promoted foam cell formation; bone marrow-restricted SIRT1 deletion confirmed macrophage-specific SIRT1 function decreases atherogenesis through LOX-1.\",\n      \"method\": \"Heterozygous SIRT1 mouse model, bone marrow transplantation, peritoneal macrophage isolation, oxLDL uptake assays, NF-κB pathway analysis\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic deletion model confirmed by bone marrow transplantation, molecular pathway (NF-κB/LOX-1) identified\",\n      \"pmids\": [\"20418343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"All tested statins directly interact with the LOX-1 C-type lectin-like domain (CTLD), filling a hydrophobic tunnel in the recognition domain, displacing fluorescent ox-LDL binding. This interaction stabilizes the LOX-1 dimer, as confirmed by electrophoresis and western blot. Molecular docking and molecular dynamics simulations identified a 'CTLD clamp motion' enabling receptor-substrate coupling.\",\n      \"method\": \"Cell-based fluorescent ox-LDL displacement assay, molecular docking simulation, molecular dynamics simulation, electrophoretic separation and western blot of dimer assembly\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based binding assay plus computational docking, western blot of dimer; single lab, multiple methods but no crystal structure or direct mutagenesis validation\",\n      \"pmids\": [\"25950192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SPPL2a/b (signal peptide peptidase-like 2a/b) perform intramembrane proteolysis of the membrane-bound N-terminal fragment (NTF) of LOX-1 generated after ectodomain shedding by ADAM10 and lysosomal degradation. LOX-1 NTFs self-associate via their transmembrane domain and activate MAP kinases in a ligand-independent manner, upregulating pro-atherogenic targets (ICAM-1, CTGF). SPPL2a/b-deficient mice accumulate LOX-1 NTFs and develop larger atherosclerotic plaques.\",\n      \"method\": \"Genetic mouse models (SPPL2a/b knockout), biochemical characterization of LOX-1 NTF, MAP kinase activation assays, identification of ADAM10 as sheddase, immunofluorescence, atherosclerosis plaque quantification\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout models combined with biochemical identification of cleavage products and downstream signaling, multiple orthogonal methods\",\n      \"pmids\": [\"30819724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LOX-1-mediated ROS generation drives autophagy and mitochondrial DNA (mtDNA) damage, which in turn activates the NLRP3 inflammasome in THP-1 macrophages and primary macrophages; LOX-1 inhibition (by blocking antibody or siRNA) inhibited ROS generation, autophagy, mtDNA damage, and NLRP3 inflammasome expression. DNase II knockdown also inhibited autophagy and NLRP3, confirming the pathway: LOX-1 → ROS → mtDNA damage → autophagy → NLRP3 activation.\",\n      \"method\": \"siRNA knockdown, blocking antibody, ROS inhibitors, autophagy inducer/inhibitor, DNase II siRNA, THP-1 and primary macrophages\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple siRNA/inhibitor interventions at different steps; single lab, but orthogonal genetic and pharmacological tools confirming pathway order\",\n      \"pmids\": [\"24776598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LOX-1 and PCSK9 positively regulate each other's expression; siRNA knockdown of PCSK9 reduced LOX-1 expression and function, while recombinant PCSK9 enhanced LOX-1 expression; conversely, LOX-1 siRNA reduced PCSK9 expression and LOX-1 overexpression increased PCSK9. In LOX-1 KO mice, PCSK9 was decreased; in PCSK9 KO mice, LOX-1 was decreased. Mitochondrial ROS (mtROS) initiates the LOX-1/PCSK9 interaction.\",\n      \"method\": \"siRNA knockdown, cDNA overexpression, recombinant protein treatment, LOX-1 KO and PCSK9 KO mouse models, western blotting, mtROS inhibitors\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — bidirectional siRNA/overexpression in cells, confirmed in two separate gene KO mouse models; multiple orthogonal approaches\",\n      \"pmids\": [\"26092101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LOX-1 pathway activation is involved in determining the extent of myocardial ischemia-reperfusion injury; LOX-1 expression is induced in cardiac myocytes following ischemia-reperfusion (but not ischemia alone). Administration of anti-LOX-1 monoclonal antibody reduced myocardial infarction size by ~50% in rats.\",\n      \"method\": \"Rat coronary artery ligation/reperfusion model, immunohistochemistry, anti-LOX-1 monoclonal antibody treatment, infarct size measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function via antibody blockade with quantitative phenotypic readout; single lab, single intervention method\",\n      \"pmids\": [\"12507499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Statins (simvastatin and atorvastatin) attenuate ox-LDL-induced upregulation of LOX-1 and downregulation of eNOS in human coronary artery endothelial cells; ox-LDL-mediated MAP kinase activation was also inhibited by statins, suggesting inhibition of LOX-1 and subsequently MAP kinase activity as a mechanism of statin cardioprotection.\",\n      \"method\": \"Cell-based assay with human coronary artery endothelial cells, western blotting for LOX-1 and eNOS, MAP kinase activation assay, dose-response with two different statins\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single lab, pharmacological modulation with dose-response, two orthogonal protein readouts; no genetic confirmation\",\n      \"pmids\": [\"11735125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LPS induces LOX-1 expression via the TLR4/MyD88/Nox4-ROS/p38MAPK/NF-κB signaling pathway in endothelial cells; siRNA for TLR4, MyD88, and Nox4 each blocked LPS-induced LOX-1 upregulation, as did inhibitors of p38MAPK, NF-κB, and NADPH oxidase. LOX-1-mediated ox-LDL uptake and monocyte-endothelial adhesion were inhibited by anti-LOX-1 antibody.\",\n      \"method\": \"siRNA knockdown of TLR4, MyD88, Nox4; pharmacological inhibitors; western blotting; DiI-ox-LDL uptake assay; monocyte adhesion assay; in vivo mouse LPS injection\",\n      \"journal\": \"Vascular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple siRNA targets and pathway inhibitors defining signal hierarchy; single lab, confirmed in vivo\",\n      \"pmids\": [\"25135647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LOX-1 inhibition impairs macrophage migration in response to ox-LDL; LOX-1 mediates ox-LDL-induced upregulation of calpain-2 and downregulation of calpain-1, and increases intracellular Ca2+; LOX-1 knockout macrophages show higher calpain-1 expression, lower calpain-2, improved migration, and lower Ca2+ compared to wild-type after ox-LDL treatment.\",\n      \"method\": \"LOX-1 knockout mouse peritoneal macrophages, wild-type comparison, calpain expression western blotting, cell migration assay, intracellular Ca2+ measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with defined cellular phenotype (migration) and molecular mechanism (calpain-1/2 regulation); single lab\",\n      \"pmids\": [\"26393906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Membrane cholesterol depletion (by MβCD) triggers release of full-length LOX-1 in exosomes and promotes ectodomain shedding to generate soluble LOX-1 (sLOX-1); endothelial cells secrete a soluble metalloproteinase responsible for LOX-1 ectodomain shedding; long-term statin treatment enhances sLOX-1 proteolytic shedding.\",\n      \"method\": \"Cholesterol modulation by MβCD and statins, exosome isolation, western blotting for full-length and truncated forms, metalloproteinase inhibition assay, stable and transient LOX-1 expression in endothelial cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical fractionation, multiple cholesterol-modulating agents and metalloproteinase inhibition; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26495844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LOX-1 transcription is upregulated by ox-LDL through an Oct-1 binding motif at nt -1556 of the human LOX-1 promoter, and by angiotensin II through an NF-κB motif at nt -2158; Oct-1-mediated upregulation represents an early transcriptional event in LOX-1 stimulation by ox-LDL, creating a positive feedback loop.\",\n      \"method\": \"Promoter analysis, transcription factor binding site mapping, reporter assays\",\n      \"journal\": \"Cardiovascular drugs and therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mapping with defined transcription factor binding sites; single lab review of experimental data, specific nucleotide positions identified\",\n      \"pmids\": [\"21796333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-98 directly targets LOX-1 mRNA (validated by luciferase reporter assay); miR-98 mimics decreased LOX-1 expression and inhibited foam cell formation and lipid accumulation in macrophages; miR-98 inhibitors had opposite effects; effects confirmed in ApoE-/- mice in vivo.\",\n      \"method\": \"Luciferase reporter assay (3'UTR), miR-98 mimics and inhibitors in peritoneal macrophages, ApoE-/- mouse model with agomiR-98 and antagomiR-98\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct target validation by luciferase reporter, bidirectional miRNA manipulation in vitro and confirmed in vivo in mouse model\",\n      \"pmids\": [\"29549823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The rs1050286 SNP in the OLR1 3'UTR alters LOX-1 expression by modifying miR-24 binding affinity; luciferase assays showed miR-24 targets OLR1 3'UTR-G but not 3'UTR-A; overexpression of miR-24 in HeLa cells (heterozygous A/G) but not HepG2 cells (homozygous A/A) significantly downregulated OLR1 mRNA and protein.\",\n      \"method\": \"Luciferase reporter assay with OLR1 3'UTR alleles, miR-24 overexpression in genotyped cell lines, RT-PCR and western blotting\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional validation of SNP effect on miRNA-mediated repression by luciferase and allele-specific cell line comparison; single lab\",\n      \"pmids\": [\"26542080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HRD1 (E3 ubiquitin ligase) interacts with LOX-1 and promotes ubiquitination and proteasomal degradation of LOX-1, thereby preventing ox-LDL-induced endothelial cell apoptosis; LOX-1 deletion attenuated endothelial apoptosis induced by HRD1 downregulation; transcription factor KLF2 positively regulates HRD1 expression and pravastatin enhanced HRD1 expression through a KLF2-dependent mechanism.\",\n      \"method\": \"Co-immunoprecipitation of HRD1 with LOX-1, ubiquitination assay, HRD1 overexpression and LOX-1 siRNA knockdown, endothelial apoptosis assay, KLF2/promoter binding assay\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying E3 ligase-substrate interaction, ubiquitination confirmed, functional apoptosis readout; single lab\",\n      \"pmids\": [\"32308114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LOX-1 mediates inflammatory activation of microglial cells through the p38-MAPK/NF-κB pathway under hypoxic-ischemic conditions; NF-κB and HIF-1α bind to the OLR1 gene promoter region (confirmed by chromatin immunoprecipitation and luciferase reporter assay); LOX-1 expression in microglial cells is autonomously maintained by positive feedback of the intracellular LOX-1 signaling pathway.\",\n      \"method\": \"Primary rat microglial cells, oxygen-glucose deprivation model, siRNA, p38-MAPK inhibitor, NF-κB inhibitor, luciferase reporter assay, chromatin immunoprecipitation assay (ChIP), ROS assay, cytokine measurement\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP validation of transcription factor binding to OLR1 promoter, multiple inhibitor/siRNA interventions; single lab, single cell type\",\n      \"pmids\": [\"37268943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Nrf2 directly binds to the LOX-1 promoter sequence and positively regulates LOX-1 transcriptional and translational activity; Nrf2 deficiency in ApoE-/- mice diminished LOX-1 expression and attenuated VSMC proliferation and migration, reducing atherosclerotic plaque burden; confirmed by dual luciferase reporter and immunoprecipitation assays.\",\n      \"method\": \"Dual luciferase reporter assay, immunoprecipitation, Nrf2-siRNA in VSMCs, Apoe-/-Nrf2-/- double knockout mouse model, proliferation and migration assays\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter interaction confirmed by luciferase reporter and IP, genetic knockout with cellular phenotype; single lab\",\n      \"pmids\": [\"35299056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LOX-1 acts as a membrane receptor for H. pylori catalase, mediating bacterial adhesion to gastric epithelial cells; LOX-1 mRNA is a key target regulated by m6A modification (added by METTL3), which destabilizes LOX-1 mRNA and reduces LOX-1 protein levels; pharmacological inhibition or genetic ablation of LOX-1 reduces H. pylori colonization; deletion of bacterial catalase decreases adhesion to human gastric sections.\",\n      \"method\": \"m6A-seq, siRNA against m6A methylases, Mettl3 hemizygous mouse model, LOX-1 pharmacological inhibition and genetic knockout, bacterial adhesion assay, identification of LOX-1 as receptor for H. pylori catalase\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic LOX-1 ablation and bacterial catalase deletion confirm receptor-ligand specificity, m6A regulation confirmed biochemically, multiple orthogonal methods in cells and in vivo\",\n      \"pmids\": [\"38253620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LOX-1 knockdown in H9C2 cardiomyocytes significantly ameliorated hypoxia-induced cell hypertrophy and reduced oxidative stress; mechanistically, LOX-1/NOX2/NOX4/ROS pathway underlies hypoxia-induced right ventricular hypertrophy; LOX-1 knockdown attenuated NOX2/4 expression and ROS generation.\",\n      \"method\": \"siRNA knockdown of LOX-1 in H9C2 cells and rat model, immunofluorescence, western blotting, DCFH-DA ROS assay, rat hypoxia model\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with quantified hypertrophy and molecular readouts in vitro and in vivo; single lab\",\n      \"pmids\": [\"28259654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"OLR1 increases HMGA2 transcription by upregulating c-Myc expression to promote metastasis of pancreatic cancer cells; OLR1 promoted proliferation and metastasis in vitro and in vivo.\",\n      \"method\": \"OLR1 overexpression and knockdown in pancreatic cancer cell lines, in vivo xenograft mouse model, c-Myc and HMGA2 expression analysis\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss- and gain-of-function with defined molecular pathway (OLR1→c-Myc→HMGA2); single lab, in vitro and in vivo confirmation\",\n      \"pmids\": [\"32019809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TBC1D3 oncogene upregulates OLR1 expression at the transcriptional level via activation of the TNFα/NF-κB signaling pathway; OLR1 depletion (by siRNA or pomalidomide) significantly decreased TBC1D3-induced migration of breast cancer cells; TBC1D3 increased TNFα release, elevated TNFR1/TRAF transcription, and decreased TNFR1 degradation to activate NF-κB.\",\n      \"method\": \"siRNA knockdown of OLR1, TBC1D3 overexpression, NF-κB inhibitor caffeic acid phenethyl ester, pomalidomide (TNFα inhibitor), cell migration assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and pharmacological inhibition with quantified migration phenotype; pathway placement via NF-κB inhibition; single lab\",\n      \"pmids\": [\"28844714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"OLR1 overexpression activates NF-κB (p65) and upregulates pro-oncogenic NF-κB target genes involved in apoptosis inhibition (BCL2, BCL2A1, TNFAIP3) and cell cycle regulation (CCND2) in both MCF10A and HCC1143 cell lines; OLR1 overexpression in HCC1143 cells enhanced cell migration; OLR1 neutralizing antibody inhibited adhesion and transendothelial migration of untreated HCC1143 cells; OLR1 KO mice showed broad inhibition of NF-κB target genes and de novo lipogenesis genes.\",\n      \"method\": \"OLR1 overexpression, OLR1 KO mouse microarray, neutralizing antibody, cell migration assay, cell adhesion and transendothelial migration assay, transcriptome analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function combined with KO mouse transcriptome; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21637860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LOX-1 in cardiac fibroblasts supports cytoskeletal organization and proliferation; as fibroblasts senesce, LOX-1 expression decreases; transfection of senescent fibroblasts with h-LOX-1 restored cytoskeletal organization, partially restored CDC42 and p70 S6 kinase expression, enhanced proliferation, and restored Mdm2 and phospho-Akt expression.\",\n      \"method\": \"Serial passage and aging mouse cardiac fibroblast isolation, LOX-1 cDNA transfection, cytoskeleton imaging, western blotting for CDC42, p70 S6 kinase, Mdm2, Akt\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — gain-of-function rescue with molecular readouts; single lab, single cell type, no genetic KO comparison\",\n      \"pmids\": [\"23648807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"miR-590-5p targets LOX-1 mRNA; Ang II downregulates miR-590-5p and upregulates LOX-1 in HUVECs; miR-590-5p mimics reduced LOX-1 expression and attenuated Ang II-induced apoptosis and ROS generation; LOX-1 siRNA or neutralizing antibody (TS92) reduced apoptosis and inhibited caspase-3 activation and cytochrome C release.\",\n      \"method\": \"miR-590-5p mimics, LOX-1 siRNA, LOX-1 neutralizing antibody (TS92), flow cytometry for apoptosis, western blotting for caspase-3 and cytochrome C, DCFH-DA for ROS\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional miRNA manipulation, genetic and antibody LOX-1 blockade, multiple apoptosis readouts; single lab\",\n      \"pmids\": [\"26906623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Klotho inhibits ox-LDL deposition in podocytes in diabetic kidney disease by reducing IGF-1R expression, which decreases RAC1 expression and enhances mitochondrial function, ultimately reducing OLR1 expression and renal ox-LDL deposition.\",\n      \"method\": \"Klotho genotype mouse model (STZ-induced DKD), in vitro podocyte experiments, siRNA/inhibitor targeting IGF-1R and RAC1, western blotting and immunofluorescence\",\n      \"journal\": \"Cardiovascular diabetology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic mouse model and in vitro pathway dissection (IGF-1R/RAC1/OLR1); single lab, multiple interventions\",\n      \"pmids\": [\"37891556\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"OLR1/LOX-1 is a Type II transmembrane C-type lectin scavenger receptor that recognizes and internalizes oxidized LDL, phosphatidylserine (Ca2+-dependent), apoptotic cells, activated platelets, bacteria (S. aureus, E. coli), and H. pylori catalase via its C-terminal lectin-like domain; upon ligand binding it activates NF-κB, p38-MAPK, and ROS-generating pathways to drive endothelial dysfunction, macrophage foam cell formation, VSMC proliferation, and inflammation in atherosclerosis; its activity is regulated proteolytically by ADAM10 (ectodomain shedding generating sLOX-1) and SPPL2a/b (intramembrane cleavage of the residual NTF, which otherwise activates MAP kinases independently of ligand), by ubiquitin-proteasomal degradation via HRD1, by its dominant-negative splice variant LOXIN (which forms non-functional hetero-oligomers reducing plasma membrane LOX-1), transcriptionally by NF-κB, HIF-1α, Oct-1, and Nrf2, and post-transcriptionally by miR-24, miR-98, and miR-590-5p; it engages in mutual positive regulation with PCSK9, is downregulated by SIRT1 (via NF-κB suppression), and is directly bound and stabilized in its hydrophobic tunnel by statins.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"OLR1/LOX-1 is a Type II transmembrane C-type lectin-like scavenger receptor whose C-terminal lectin domain mediates recognition and internalization of multiple ligands, driving vascular inflammation and atherogenesis [#0, #4]. Its lectin-like extracellular domain is N-glycosylated, and active-site mutagenesis identified conserved positively charged residues required for oxidized LDL binding; the domain also binds phosphatidylserine in a strictly Ca2+-dependent manner (enabling apoptotic-body recognition), adheres Gram-positive and Gram-negative bacteria independently of divalent cations, and serves as a receptor for H. pylori catalase to mediate gastric colonization [#0, #1, #2, #21]. Ligand engagement activates p38-MAPK and NF-\\u03baB signaling and ROS generation, upregulating adhesion molecules (VCAM-1, ICAM-1) and impairing eNOS; endothelial-specific LOX-1 overexpression is sufficient to drive macrophage accumulation and atherosclerotic plaque formation in vivo [#4, #7]. Downstream of receptor activation, LOX-1-generated ROS cause mitochondrial DNA damage and autophagy that activate the NLRP3 inflammasome, regulate calpain-1/calpain-2 balance and intracellular Ca2+ to control macrophage migration, and engage the NOX2/NOX4 axis in cardiomyocyte hypertrophy [#8, #13, #22]. LOX-1 is subject to multilayered control: ADAM10-mediated ectodomain shedding releases soluble LOX-1 and leaves a membrane N-terminal fragment that self-associates and activates MAP kinases ligand-independently until cleared by SPPL2a/b intramembrane proteolysis; HRD1-dependent ubiquitination targets it for proteasomal degradation; and the splice variant LOXIN hetero-oligomerizes with LOX-1 to reduce its surface expression [#3, #7, #18]. Its expression is transcriptionally driven by Oct-1, NF-\\u03baB, HIF-1\\u03b1, and Nrf2 through defined promoter elements, repressed by SIRT1 via NF-\\u03baB suppression, and post-transcriptionally tuned by miR-98, miR-24, miR-590-5p, and m6A methylation [#5, #15, #16, #20, #16]. LOX-1 engages in mutual positive regulation with PCSK9 initiated by mitochondrial ROS, and statins directly bind its lectin-domain hydrophobic tunnel to displace ox-LDL and stabilize the receptor dimer [#9, #6]. Beyond the vasculature, OLR1 promotes proliferation and metastasis of pancreatic and breast cancer cells through c-Myc/HMGA2 induction and NF-\\u03baB target gene activation [#23, #24, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that LOX-1 is a pattern-recognition receptor with ligand breadth beyond oxidized LDL, binding bacteria independently of cations or serum.\",\n      \"evidence\": \"FITC-labeled bacterial binding to LOX-1-expressing CHO-K1 and aortic endothelial cells with antibody/inhibitor blockade\",\n      \"pmids\": [\"11290792\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding motif on bacteria not defined\", \"physiological consequence of bacterial binding not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Linked statins to LOX-1 by showing they suppress ox-LDL-induced LOX-1 upregulation and downstream MAP kinase activation, framing a cardioprotective mechanism.\",\n      \"evidence\": \"Western blotting for LOX-1/eNOS and MAP kinase assays in human coronary artery endothelial cells with two statins\",\n      \"pmids\": [\"11735125\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic confirmation\", \"did not distinguish transcriptional vs post-translational effects\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the structural basis of ligand recognition, locating the functional binding determinants in the C-type lectin domain and documenting glycosylation and ectodomain shedding.\",\n      \"evidence\": \"Active-site mutagenesis, glycosylation studies, and cleavage/shedding assays\",\n      \"pmids\": [\"12163130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sheddase identity not established here\", \"no atomic structure of ligand-bound domain\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed LOX-1 directly and selectively recognizes phosphatidylserine in a Ca2+-dependent manner, providing a molecular basis for apoptotic-cell clearance.\",\n      \"evidence\": \"Recombinant folded glycosylated protein lipid-specificity panel, Ca2+/Mg2+ substitution, apoptotic-body recognition with blocking antibodies\",\n      \"pmids\": [\"16146427\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ca2+ coordination site not mapped\", \"in vivo relevance of PS recognition not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified a dominant-negative regulatory mechanism whereby the splice variant LOXIN suppresses LOX-1 by hetero-oligomerization and reduced surface localization.\",\n      \"evidence\": \"Reciprocal Co-IP and ox-LDL uptake/membrane localization assays in fibroblasts and endothelial cells\",\n      \"pmids\": [\"18191942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of hetero-oligomers unknown\", \"endogenous LOXIN regulation not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed SIRT1 as a negative regulator of LOX-1, reducing macrophage foam cell formation through NF-\\u03baB suppression.\",\n      \"evidence\": \"SIRT1 heterozygous and bone-marrow-restricted deletion in atherosclerotic mice with macrophage oxLDL uptake assays\",\n      \"pmids\": [\"20418343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SIRT1 target at the OLR1 locus not defined\", \"deacetylation substrate in the pathway unidentified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapped stimulus-specific transcriptional control of OLR1, identifying an Oct-1 element responding to ox-LDL and an NF-\\u03baB element responding to angiotensin II, defining a feed-forward loop.\",\n      \"evidence\": \"Promoter mapping, transcription-factor binding-site analysis, reporter assays\",\n      \"pmids\": [\"21796333\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ChIP confirmation of Oct-1 occupancy not shown\", \"in vivo relevance of specific sites not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Extended OLR1 function to oncogenesis, showing it activates NF-\\u03baB target genes promoting survival, cell cycle, and migration in breast epithelial/cancer cells.\",\n      \"evidence\": \"Overexpression, KO mouse transcriptome microarray, neutralizing antibody, adhesion/transendothelial migration assays\",\n      \"pmids\": [\"21637860\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ligand driving tumor NF-\\u03baB activation unclear\", \"mechanism of surface signaling in cancer not dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed a non-scavenging role in which LOX-1 supports cytoskeletal organization and proliferation in cardiac fibroblasts, declining with senescence.\",\n      \"evidence\": \"LOX-1 cDNA rescue of senescent fibroblasts with CDC42/p70S6K/Mdm2/Akt readouts and cytoskeleton imaging\",\n      \"pmids\": [\"23648807\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No KO comparison\", \"direct link from receptor to cytoskeletal effectors not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that endothelial LOX-1 alone is sufficient to drive atherosclerosis via p38/NF-\\u03baB, ROS, VCAM-1, and eNOS impairment.\",\n      \"evidence\": \"Endothelial-specific Tie2 transgenic mice on ApoE-/- background with bone marrow transplantation epistasis and intravital imaging\",\n      \"pmids\": [\"24419805\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of macrophage LOX-1 not isolated here\", \"structural basis of receptor signaling not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined an ordered intracellular cascade by which LOX-1-driven ROS cause mtDNA damage and autophagy to activate the NLRP3 inflammasome.\",\n      \"evidence\": \"siRNA, blocking antibody, ROS/autophagy modulators, and DNase II knockdown in THP-1 and primary macrophages\",\n      \"pmids\": [\"24776598\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"in vivo confirmation of the inflammasome axis not shown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed LPS induces LOX-1 through a defined TLR4/MyD88/Nox4-ROS/p38/NF-\\u03baB hierarchy, connecting innate immune signaling to receptor upregulation.\",\n      \"evidence\": \"siRNA of TLR4/MyD88/Nox4, pathway inhibitors, ox-LDL uptake and monocyte adhesion assays, in vivo LPS injection\",\n      \"pmids\": [\"25135647\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter target downstream of NF-\\u03baB not mapped here\", \"single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Implicated the LOX-1 pathway in myocardial ischemia-reperfusion injury, with induction specific to reperfusion and antibody blockade halving infarct size.\",\n      \"evidence\": \"Rat coronary ligation/reperfusion model with anti-LOX-1 mAb and infarct quantification\",\n      \"pmids\": [\"12507499\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ligand driving reperfusion induction unclear\", \"single intervention method\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established reciprocal positive regulation between LOX-1 and PCSK9 initiated by mitochondrial ROS, linking two atherogenic factors.\",\n      \"evidence\": \"Bidirectional siRNA/overexpression/recombinant protein in cells confirmed in LOX-1 KO and PCSK9 KO mice with mtROS inhibitors\",\n      \"pmids\": [\"26092101\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mediator of the cross-regulation not identified\", \"whether interaction is direct or indirect unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed statins directly bind the LOX-1 lectin-domain hydrophobic tunnel, displacing ox-LDL and stabilizing the receptor dimer.\",\n      \"evidence\": \"Cell-based ox-LDL displacement, molecular docking/dynamics, and electrophoresis/western blot of dimer assembly\",\n      \"pmids\": [\"25950192\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No crystal structure\", \"binding residues not validated by mutagenesis\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified cholesterol-dependent release routes for LOX-1, including exosomal export of full-length receptor and metalloproteinase-mediated ectodomain shedding enhanced by statins.\",\n      \"evidence\": \"M\\u03b2CD/statin cholesterol modulation, exosome isolation, metalloproteinase inhibition, western blotting in endothelial cells\",\n      \"pmids\": [\"26495844\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific metalloproteinase not identified here\", \"functional role of exosomal LOX-1 unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected a 3'UTR SNP (rs1050286) to allele-specific miR-24 repression of OLR1, providing a genetic mechanism for expression variation.\",\n      \"evidence\": \"Luciferase assays with OLR1 3'UTR alleles and miR-24 overexpression in genotyped cell lines\",\n      \"pmids\": [\"26542080\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Population-level phenotype not linked\", \"single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed LOX-1 controls macrophage migration via calpain-1/calpain-2 balance and intracellular Ca2+ in response to ox-LDL.\",\n      \"evidence\": \"LOX-1 KO peritoneal macrophages, calpain western blotting, migration and Ca2+ assays\",\n      \"pmids\": [\"26393906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking receptor to calpain switch not defined\", \"single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified miR-590-5p as a repressor of LOX-1 protecting endothelial cells from angiotensin II-induced apoptosis and ROS.\",\n      \"evidence\": \"miR-590-5p mimics, LOX-1 siRNA/neutralizing antibody, apoptosis flow cytometry, caspase-3/cytochrome C western blotting\",\n      \"pmids\": [\"26906623\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct 3'UTR binding validation limited\", \"in vivo confirmation absent\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended hypoxia-driven LOX-1 signaling to microglia, with ChIP-confirmed NF-\\u03baB and HIF-1\\u03b1 promoter binding and an autonomous positive-feedback loop.\",\n      \"evidence\": \"Oxygen-glucose deprivation in primary microglia, ChIP, luciferase reporters, siRNA and pathway inhibitors\",\n      \"pmids\": [\"37268943\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo neuroinflammation relevance not tested\", \"single cell type\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Implicated LOX-1 in hypoxia-induced cardiomyocyte hypertrophy through a NOX2/NOX4/ROS pathway.\",\n      \"evidence\": \"LOX-1 siRNA in H9C2 cells and rat hypoxia model with hypertrophy and ROS readouts\",\n      \"pmids\": [\"28259654\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor ligand in hypoxia unclear\", \"single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed OLR1 promotes pancreatic cancer proliferation and metastasis through a c-Myc/HMGA2 transcriptional axis.\",\n      \"evidence\": \"Overexpression/knockdown in pancreatic cancer lines, xenograft model, c-Myc/HMGA2 expression analysis\",\n      \"pmids\": [\"32019809\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Link from surface receptor to c-Myc induction not mechanistically resolved\", \"single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed OLR1 downstream of the TBC1D3 oncogene via TNF\\u03b1/NF-\\u03baB signaling driving breast cancer migration.\",\n      \"evidence\": \"TBC1D3 overexpression, OLR1 siRNA/pomalidomide, NF-\\u03baB inhibitor, migration assays\",\n      \"pmids\": [\"28844714\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct OLR1 promoter occupancy not shown\", \"single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Resolved the proteolytic fate of LOX-1, showing ADAM10 sheds the ectodomain and SPPL2a/b clear the residual NTF, which otherwise self-associates to activate MAP kinases ligand-independently and drive atherosclerosis.\",\n      \"evidence\": \"SPPL2a/b knockout mice, biochemical characterization of NTF, MAP kinase assays, plaque quantification\",\n      \"pmids\": [\"30819724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of NTF self-association undefined\", \"regulation of ADAM10 shedding in vivo not detailed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified HRD1 as the E3 ligase ubiquitinating LOX-1 for proteasomal degradation, with KLF2-driven HRD1 protecting endothelium from ox-LDL-induced apoptosis.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, HRD1 overexpression/LOX-1 siRNA, apoptosis assay, KLF2 promoter binding\",\n      \"pmids\": [\"32308114\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site on LOX-1 not mapped\", \"single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established Nrf2 as a direct positive transcriptional regulator of LOX-1 promoting VSMC proliferation and plaque burden.\",\n      \"evidence\": \"Dual luciferase reporter, immunoprecipitation, Nrf2 siRNA in VSMCs, ApoE-/-Nrf2-/- double-knockout mice\",\n      \"pmids\": [\"35299056\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Exact Nrf2 response element not delineated\", \"single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected Klotho-dependent IGF-1R/RAC1 signaling to OLR1 suppression, reducing ox-LDL deposition in diabetic kidney podocytes.\",\n      \"evidence\": \"Klotho genotype STZ-DKD mouse model and podocyte IGF-1R/RAC1 siRNA/inhibitor experiments\",\n      \"pmids\": [\"37891556\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional control of OLR1 not shown\", \"single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified LOX-1 as the host receptor for H. pylori catalase mediating gastric colonization, and showed METTL3-driven m6A destabilizes OLR1 mRNA.\",\n      \"evidence\": \"m6A-seq, METTL3 siRNA/Mettl3 hemizygous mice, LOX-1 inhibition/knockout, bacterial catalase deletion adhesion assays\",\n      \"pmids\": [\"38253620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalase-binding interface on LOX-1 not mapped\", \"downstream signaling from this interaction not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How LOX-1's diverse ligand recognition is structurally encoded and translated into distinct downstream signaling outputs across cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of ligand-bound LOX-1\", \"no defined transmembrane signaling adaptor for the receptor\", \"mechanism distinguishing ligand-dependent from NTF-mediated signaling unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0, 1, 2, 21]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [1, 21]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [4, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 4]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 8, 12, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 7, 9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 23, 24]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [7, 18]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [15, 16, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LOXIN\", \"PCSK9\", \"HRD1\", \"ADAM10\", \"SPPL2a\", \"SPPL2b\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}